Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Abemaciclib (Verzenio) for Metastatic Breast Cancer
(Notification to Implement Issued as of July 22, 2019)

Ixazomib (Ninlaro) for Multiple Myeloma (2nd-beyond)
(Notification to Implement Issued as of July 22, 2019)

Daratumumab (Darzalex) for Multiple Myeloma
(Open for Input on Submission until July 31, 2019)

Midostaurin (Rydapt) for Systemic Mastocytosis
(Pending Submission as of July 15, 2019)

Gemtuzumab Ozogamicin (Brand Name: TBD) for Acute Myeloid Leukemia
(Pending Submission as of July 11, 2019)

Cemiplimab (Libtayo) for Advanced Cutaneous Squamous Cell Carcinoma
(Open for Input on Submission until July 23, 2019)

Pembrolizumab (Keytruda) for Renal Cell Carcinoma
(Pending Submission as of July 5, 2019)

Daratumumab (Darzalex) in combination with Bortezomib, Melphalan and Prednisone for Multiple Myeloma
(Open for Feedback on Recommendation until July 19, 2019)

Lenvatinib (Lenvima) for Hepatocellular Carcinoma
(Open for Feedback on Recommendation until July 19, 2019)

Trifluridine-Tipiracil (Lonsurf) Resubmission for Metastatic Colorectal Cancer
(Open for Feedback on Recommendation until July 19, 2019)

Entrectinib (Brand Name: TBD) for Neurotrophic Tyrosine Receptor Kinase Positive Solid Tumours
(Pending Submission as of June 28, 2019)

Abiraterone (Zytiga) for Prostate Cancer Resubmission
(Pending Submission as of June 26, 2019)

Find a Drug Review